Stoke Therapeutics Inc (STOK) announced Loss for fourth quarter that decreased from last year and beat the Street estimates.
The company's bottom line totaled -$10.48 million, or -$0.18 per share. This compares with -$26.96 million, or -$0.60 per share, last year.
Analysts on average had expected the company to earn -$0.53 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 707.5% to $22.61 million from $2.80 million last year.
Stoke Therapeutics Inc earnings at a glance (GAAP) :
-Earnings: -$10.48 Mln. vs. -$26.96 Mln. last year.
-EPS: -$0.18 vs. -$0.60 last year.
-Revenue: $22.61 Mln vs. $2.80 Mln last year.
For comments and feedback: editorial@rttnews.com